Scilex announced that it has the FDA approval of commercial manufacturing of Gloperba, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and will launch in June. Scilex will stock Gloperba in all major wholesalers and pharmacies starting June 10, the company said in a statement. Scilex added that it has a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCLX:
- Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024
- Scilex Alerts Regulators to Illegal Stock Manipulation
- Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company
- Scilex sends letter to SEC, FINRA over ‘illegal market manipulation’
- Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index